ROOT JONATHAN D 4

What Happened

• Jonathan D. Root, a director of Edgewise Therapeutics, received a grant of 16,377 stock options (derivative securities) on June 5, 2026. The grant was reported at a $0.00 per-share acquisition price (no cash exchanged). This was an award/grant (code A), not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-05; Filing date: 2026-07-17 (filing appears late relative to the 2-business-day Form 4 reporting rule).
• Security: Stock options (derivative). Quantity: 16,377 options. Reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: 100% of these stock options will vest on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders.
• No indication of an exercise, sale, 10b5-1 plan, or tax-withholding event in the provided information.

Context

• This was an equity compensation grant (option award) typical for directors; it does not reflect an immediate purchase or sale of stock. Such awards are common as part of director pay and should be interpreted as compensation rather than a direct bullish or bearish market signal. The late filing could be administrative; investors monitoring insider activity should note the grant date (June 5, 2026) rather than the filing date.